FDA APPROVES ABRAXANE® FOR THE FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER ·
FDA APPROVES ABRAXANE® FOR THE FIRST-LINE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER
· Approval Based on Significantly Improved Overall Response Rates in all Patients Regardless of Histology
· Adds a New Therapeutic Option for Patients with Lung Cancer, the Leading Cause of Cancer Deaths in the United States
















